Bayer Schering Pharma at the 2nd International Congress on
‘Prediabetes’ and the Metabolic Syndrome – 25–28 April 2007
‘Prediabetes’ and the Metabolic Syndrome – 25–28 April 2007
Barcelona April 2007 - Bayer Schering Pharma organised a number of events at the 2nd International Congress on ‘Prediabetes’ and the Metabolic Syndrome held in Barcelona, Spain this month, to announce that a major new Glucobay trial, the Acarbose Cardiovascular Evaluation (ACE), will start in 2007. The design of and rationale for the trial were presented in detail during a press conference, a sponsored satellite symposium and a Meet-the-Expert session for delegates from the Asia-Pacific region.
The primary endpoint of ACE will be the effect of acarbose treatment on the occurrence of secondary cardiovascular events. Results are expected in 2013. Professor Avraham Karasik, chairman of the congress, commended Bayer on their ongoing commitment to clinical research, emphasising the potential of ACE to confirm that managing dysglycaemia can substantially reduce the risk of cardiovascular disease.
It is anticipated that ACE will support and extend the findings of the Study to Prevent Non-Insulin Dependent Diabetes Mellitus (STOP-NIDDM), a randomised, placebo-controlled trial which found that treatment with acarbose significantly reduces the risk of progression from prediabetes to type 2 diabetes, as well as significantly reducing the risk of a first cardiovascular event.
Bayer’s meetings were the focus for lively and informative discussions. In addition to ACE, the congress saw the launch of a new IDF consensus statement on the prevention of type 2 diabetes, which included a recommendation that Glucobay be considered for the management of prediabetes. Glucobay is still the only oral antidiabetes agent to be licensed for the treatment of prediabetes.
The Barcelona Congress – the only international congress dedicated to prediabetes – provides a forum for doctors and the pharmaceutical industry to present their studies and exchange ideas, reflecting the growing importance of early screening for and diagnosis of dysglycaemia, and the need for proactive intervention. In particular, experts emphasised the need for increased collaboration between diabetologists and cardiologists. Both ACE and the IDF consensus statement demonstrate that Glucobay remains a valuable therapy in the integrated management of dysglycaemia and its associated cardiovascular risk.
Download Programme Satellite Symposium
(pdf, 173 KB)
The primary endpoint of ACE will be the effect of acarbose treatment on the occurrence of secondary cardiovascular events. Results are expected in 2013. Professor Avraham Karasik, chairman of the congress, commended Bayer on their ongoing commitment to clinical research, emphasising the potential of ACE to confirm that managing dysglycaemia can substantially reduce the risk of cardiovascular disease.
It is anticipated that ACE will support and extend the findings of the Study to Prevent Non-Insulin Dependent Diabetes Mellitus (STOP-NIDDM), a randomised, placebo-controlled trial which found that treatment with acarbose significantly reduces the risk of progression from prediabetes to type 2 diabetes, as well as significantly reducing the risk of a first cardiovascular event.
Bayer’s meetings were the focus for lively and informative discussions. In addition to ACE, the congress saw the launch of a new IDF consensus statement on the prevention of type 2 diabetes, which included a recommendation that Glucobay be considered for the management of prediabetes. Glucobay is still the only oral antidiabetes agent to be licensed for the treatment of prediabetes.
The Barcelona Congress – the only international congress dedicated to prediabetes – provides a forum for doctors and the pharmaceutical industry to present their studies and exchange ideas, reflecting the growing importance of early screening for and diagnosis of dysglycaemia, and the need for proactive intervention. In particular, experts emphasised the need for increased collaboration between diabetologists and cardiologists. Both ACE and the IDF consensus statement demonstrate that Glucobay remains a valuable therapy in the integrated management of dysglycaemia and its associated cardiovascular risk.
Download Programme Satellite Symposium
(pdf, 173 KB)
